Clinical Trial Update: CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial CT-2103 for recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED